CD8A and cancer: LXR activation diminished infiltration of MDSCs and increased CD4+CD8+ effector T cells (Teffs) by lowering cancer-related gene expression (Spp1, S100a9, Anxa1, Mfge8, Cd14), suggesting LXR agonism to boost immune control in fibrotic tumors.